Answer quality does matter alot. But so does what happens after.
For Context
Working at Bytespace Labs has been my first time delving deep into the healthcare space.
My first impression of the industry is that is a very tricky vertical to be in, especially being in tech and working with AI and making an AI product. As I've eventually learned, the majority of the industry is not very eager to adapt these new tools compared to the tech industry as working with people's lives requires more caution than what experimenting with these things allow.
Even so, AI companies are starting to take this space more seriously. OpenAI has LifeSciBench, GPT-Rosalind, and life-sciences workflows inside Codex. Anthropic has Claude for life sciences, BioMysteryBench, and tools aimed at bioinformatics, protocols, literature synthesis, and scientific workflows.
This is only the start of the general trend moving towards research and biology work, and there's probably many more companies that will emerge that will try to accelerate innovation in this space.
As such, it's only all the more important that we approach this carefully.
Here's my take: We need to focus more on improving communication rather than reasoning in these healthcare AI products.
The Model Is Not The Product
GPT-Rosalind is a good example of this. OpenAI introduced it in April 2026 as a purpose-built life sciences model for biology, drug discovery, and translational medicine. The name comes from Rosalind Franklin, whose work helped reveal the structure of DNA and shaped modern molecular biology.
What makes this model interesting is not just that it is better at biology questions. It is that OpenAI is positioning it around scientific workflows: reasoning across papers, datasets, tools, and experiments.
That tells me something about where healthcare AI products are going. The model matters, but the model by itself is not enough. A researcher does not only need an answer. They need to know what evidence was used, what tool was called, what assumption was made, and what output can be reviewed or reused by someone else.
In that sense, GPT-Rosalind is less interesting as a chatbot and more interesting as a sign of the product layer around biology AI: tools, provenance, repeatable workflows, and governance.
Artifact Creation Is The Bottleneck
Models are getting good enough at parts of reasoning that the bottleneck starts moving elsewhere.
In healthcare, this means thinking more about getting the work into a shape that other people can understand, check, and use.
This is usually in the form of a report, notebook, chart, protocol draft, literature review, or patient-facing summary all have the same product requirement: they need to carry their context with them. Where did the claim come from? What data was used? What changed between the raw input and the final output? What still needs review?
That is where it gets hard. The model can move quickly, but the work still has to pass between researchers, clinicians, reviewers, analysts, engineers, and eventually to the patients. If the output cannot survive those handoffs, the product is incomplete.
The product has to preserve enough context that someone else can inspect it, share it, rerun it, or improve it without reconstructing the whole conversation.
Testing The Idea
I wanted to test this at a smaller scale, so I used the 2025 paper MLOmics: Cancer Multi-Omics Database for Machine Learning.
MLOmics is a cancer multi-omics database and machine-learning benchmark. The paper's contribution is the resource itself: curated cancer datasets, prepared tasks, multiple molecular data layers, and benchmark-ready formats for model evaluation.
I used it less as a biology claim to prove and more as a product test. Could an AI-assisted workflow help turn one slice of a real biology benchmark into something runnable, inspectable, and easier to hand off?
The dataset I used was GS-COAD, a colon adenocarcinoma dataset using mRNA expression data. I worked with the Top feature version: 260 samples by 5,000 mRNA features, with numeric labels from 0 to 3.
The workflow was intentionally small. I loaded the official CSV files, reshaped the expression matrix, visualized the samples with PCA and UMAP, trained Logistic Regression and Random Forest classifiers, reported accuracy and F1 scores, generated confusion matrices, and listed the most important model features.
| Model | Accuracy | Weighted F1 | Macro F1 |
|---|---|---|---|
| Logistic Regression | ~0.862 | ~0.857 | ~0.594 |
| Random Forest | ~0.769 | ~0.701 | ~0.374 |
Logistic Regression reached about 86% accuracy on an internal test split. Random Forest reached about 77%.
The lower macro F1 mattered more than the headline accuracy. It suggested the models were probably doing much better on some classes than others. That is the kind of thing a clean summary can hide and a runnable workflow can expose.
This sounds like a lot of information. And it is. But what I found myself pondering on aside from these metrics is the other things that is beside it. The source links, downloaded data, preprocessing notes, plots, model outputs, caveats, and the questions that still needed more context.
The Proper Way of Context Preservation
A healthcare AI product has to preserve the parts of the work that make the output usable after the first answer.
It should keep the source trail. If a claim came from a paper, report, guideline, dataset, or note, the user should be able to trace it.
It should keep the transformation trail. If data was cleaned, filtered, normalized, summarized, or plotted, those steps should not vanish.
It should keep the review trail. If something is exploratory, uncertain, unverified, or outside the model's authority, the product should make that obvious.
It should keep the output alive. The result should be editable, rerunnable, shareable, and easy to improve.
What We Still Need to be Cautious Of
It is still very important to stay cautious with how we use AI in this context.
AI can explain a concept beautifully and still be wrong. It can cite a paper that does not support the claim. It can generate a chart from a bad preprocessing choice. It can make an exploratory result feel more certain than it is.
This gets dangerous quickly. A clean notebook is not the same thing as understanding. A high accuracy score is not the same thing as a meaningful clinical claim. A generated explanation is not the same thing as validation. These things need to be validated more than ever.
Thus, we need to add guardrails. The product needs friction in the right places. Open the sources. Track the data. Keep the code. Make assumptions visible. Separate exploratory analysis from clinical claims. Do not hide the parts that still need domain review.
Where This Leaves Us
The healthcare industry is very broad. That's why it's hard to make the perfect product.
But the direction we need to take feels clear to me: the answer quality matters. We already have this down. But we have to start caring about what we can do beyond this.
That is the kind of healthcare AI product that we need. A system that helps serious people produce work that can be inspected, rerun, reviewed, and trusted will make a big leap in this vertical.